CClinicalTrials.gg
Sign In
CompletedNCT02518165Updated Jan 31, 2018

The Effects of A Proprietary Spearmint Extract on Cognitive Performance

An interventional study of Proprietary spearmint extract and Placebo in Mood, Cognitive Performance and Sleep, sponsored by Kemin Foods LC. Completed at 1 site in United States. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-01-31.

Sponsored by Kemin Foods LC · Not applicable, Interventional, and Other

Phase
Not applicable
Study type
Interventional
Enrollment
142
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Study summary

This study was designed to evaluate the chronic effects of a proprietary spearmint extract over 90 days of supplementation on aspects of cognitive performance (cognitive function and active reaction time), subjective mood, and sleep quality in healthy men and women.

02

Conditions studied

  • Mood
  • Cognitive Performance
  • Sleep

Keywords

  • Cognitive Domain: Speed
  • Cognitive Domain: Reaction Time
  • Cognitive Domain: Attention
  • Cognitive Domain: Executive Function
  • Cognitive Domain Memory
  • Sleep Quality
  • Sleep Efficiency
03

In context

Lead sponsor

Kemin Foods LC is the lead sponsor of 8 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Men and pre-menopausal women, 18-50 years of age.
  • Body mass index 18.5-29.99 kg/m2, inclusive or body mass index 30.0-34.99 kg/m2 and body fat via bioimpedance \<39% for women aged 18-39y, \<40% for women aged 40-50y, \<25% for men aged 18-39y, \<28% for men aged 40-50y.
  • Participant has at least a high school diploma or the equivalent.
  • Participant is recreationally active.
  • Participant is judged by the Investigator to be in general good health.
  • Participant understands the study procedures and signs forms providing informed consent to participate in the study and authorization for release of relevant protected health information to the study Investigators.

Exclusion criteria

Exclusion Criteria:

  • Participant is unable to understand and/or perform required tests.
  • Participant is unwilling to maintain normal dietary (including vitamins and supplements), exercise, sleep and medication patterns throughout the study.
  • Participant is a habitual consumer of mint tea defined as >8oz per day.
  • Participant is regularly taking a cognitive enhancing supplement.
  • Participant has a history or presence of a clinically important cardiac, renal, hepatic, endocrine, pulmonary, biliary, gastrointestinal, pancreatic, or neurologic disorder.
  • Participant has a sleep disorder or occupation where sleep during the overnight hours is irregular.
  • Participant is pregnant, planning to be pregnant during the study period, lactating, or is of childbearing potential and is unwilling to commit to the use of a medically approved form of contraception throughout the study period.
  • Participant is a current user of tobacco (defined as tobacco use within the previous 6 months).
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
142 participants (actual)

Study arms

  • Active comparator
    Proprietary spearmint extract

    Subjects randomized into the active treatment group will be asked to consume 900 mg/day of the proprietary spearmint extract.

    Dietary Supplement: Proprietary spearmint extract

  • Placebo comparator
    Microcrystalline cellulose

    Subjects randomized into the placebo group will be asked to consume 900 mg/day of the excipient, microcrystalline cellulose.

    Other: Placebo

Interventions

  • Dietary supplementProprietary spearmint extract

    Water extracted spearmint extract

  • OtherPlacebo

    Microcrystalline Cellulose

06

What researchers measure

Primary outcomes

  1. Choice reaction time as assessed by the Makoto Arena Device

    Time frame: Change from baseline after 90 days of supplementation

Secondary outcomes

  1. Cognitive function (speed, reaction time, attention, executive function, memory, and motor speed) as assessed by a computerized test battery

    Time frame: Change from baseline after 90 days of supplementation

  2. Subjective mood as assessed using a Likert scale questionnaire

    Time frame: Change from baseline after 90 days of supplementation

  3. Subjective sleep quality and efficiency as assessed using Likert and visual analog scale questionnaires

    Time frame: Change from baseline after 90 days of supplementation or between group comparisons at day 90.

07

Study locations

1 site
  • Musclepharm Sports Science Institute
    Denver, Colorado 80239, United States
08

References and documents

Publications

  • Falcone PH, Tribby AC, Vogel RM, Joy JM, Moon JR, Slayton CA, Henigman MM, Lasrado JA, Lewis BJ, Fonseca BA, Nieman KM, Herrlinger KA. Efficacy of a nootropic spearmint extract on reactive agility: a randomized, double-blind, placebo-controlled, parallel trial. J Int Soc Sports Nutr. 2018 Dec 12;15(1):58. doi: 10.1186/s12970-018-0264-5. PubMed 30541572 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 31, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02518165
Lead sponsor
Kemin Foods LC
Collaborators
MusclePharm Sports Science Institute
Responsible party
Sponsor
First posted
Aug 7, 2015
Start date
Apr 2015
Primary completion
Jan 2017
Completion
Apr 2017
Last update
Jan 31, 2018

Study contacts

Jordan R Moon, PhD
principal investigator · MusclePharm Sports Science Institute

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies from this sponsor

Kemin Foods LC

Start the discussion